Perspectives on the Management of Chronic GVHD

A panel of experts discusses the types of graft versus host disease and the biologic pathways that are thought to be involved.

Catherine Lee explains risk factors that may contribute to the likelihood of a patient developing graft versus host disease.

Yi-Bin Chen leads the panel in a review of various GVHD prophylaxis regimens.

Colleen Danielson, NP shares the signs and symptoms she commonly sees in patients with graft versus host disease.

Dr Chen presents statistics on the incidence of chronic graft versus host disease.

The panelists share their insights on the identification of patients at high risk for GVHD.

Colleen Danielson, NP, walks through how chronic GVHD symptoms are assessed.

Corey Cutler details the NIH Clinical Scoring of Organ System for chronic GHVD symptoms.

Dr Lee shares an overview of therapy and supportive care options for chronic GVHD according to the severity of a symptom.

Dr Chen and Dr Cutler review a clinical case and discuss GVHD assessment for the patient.

The group discusses treatment goals and patient education for chronic GVHD.

The categories of steroid refractory gvhd are discussed: intolerant, unresponsive, and dependent.

Experts in the treatment of graft versus host disease evaluate second-line agents for patients with steroid-refractory disease.

Catherine Lee reviews data on use of ibrutinib for steroid-refractory chronic graft versus host disease.

The panel discusses the iNTERGRATE trial of ibrutinib in combination with prednisone as frontline therapy for chronic GVHD.

Yi-Bin Chen reviews data from the REACH3 trial of ruxolitinib in patients with chronic steroid-refractory graft versus host disease.

Experienced hematologist-oncologists offer their clinical experiences with ruxolitinib.

Corey Cutler explains the ROCKstar clinical trial of belumosudil for steroid-refractory chronic GVHD.

Clinical experiences with belusmosudil are shared among the panel.

The clinical trial of a novel agent, axatilimab, is reviewed and analyzed.

The panel debates the various treatment options and comments on when they prefer each one.

Chronic GVHD specialists share commentary on long-term effects of graft versus host disease and therapies for the condition.

Closing the program on chronic graft versus host disease, the panelists share what they are most looking forward to in the space.